Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>JBM Healthcare is a Hong Kong-based company engaged in the development, manufacture, and distribution of branded healthcare products, with a focus on branded medicines, proprietary Chinese medicines, and health and wellness products.</li>
 <li>The company has demonstrated strong financial growth, with a compound annual growth rate (CAGR) in revenue of approximately 24% from fiscal year 2021 to 2024, and expanding net margins.</li>
 <li>JBM Healthcare's strategy focuses on strengthening its brand equity, expanding its product portfolio, and extending its market reach, particularly in Greater China and Southeast Asia.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  JBM Healthcare is a Hong Kong-based company engaged in the development, manufacture, and distribution of branded healthcare products, with a focus on branded medicines, proprietary Chinese medicines, and health and wellness products.
  The company has demonstrated strong financial growth, with a compound annual growth rate (CAGR) in revenue of approximately 24% from fiscal year 2021 to 2024, and expanding net margins.
  JBM Healthcare's strategy focuses on strengthening its brand equity, expanding its product portfolio, and extending its market reach, particularly in Greater China and Southeast Asia.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: JBM Healthcare Ltd (1817825D HK) - May 2026

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Xiamen Yan Palace Bioengineering / Equity Capital Markets

Xiamen Yan Palace Bioengineering (XIAMEN HK)

<ul>
<li>From 2020 to 2022, Yan Palace has spent RMB831 million on advertising and promotion, while total net profit of the Company during the same period was only about RMB500 million.</li>
<li>OneNest is the main product with the highest gross margin, which is driven by price increase strategy.However, raising price may not work. Revenue growth in 2023H2/2024 could further slow down.</li>
<li>The question is are investors really satisfied with such low-margin business for a company with strong consumption attributes? Valuation of Yan Palace should be lower than <a href="https://www.smartkarma.com/entities/dong-e-e-jiaoco-ltd-a" target="_blank" data-smartkarma-citation="entities:8470:1" rel="noopener">Dong E E Jiao</a>.</li>
</ul>


From 2020 to 2022, Yan Palace has spent RMB831 million on advertising and promotion, while total net profit of the Company during the same period was only about RMB500 million.
OneNest is the main product with the highest gross margin, which is driven by price increase strategy.However, raising price may not work. Revenue growth in 2023H2/2024 could further slow down.
The question is are investors really satisfied with such low-margin business for a company with strong consumption attributes? Valuation of Yan Palace should be lower than Dong E E Jiao.


Pre-IPO Xiamen Yan Palace Bioengineering (PHIP Updates) - Some Points Worth the Attention

JBM Healthcare Ltd / Equity Capital Markets

In 2020Q3, <a href="https://www.smartkarma.com/entities/jbm-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:31085:1" rel="noopener">JBM Healthcare Ltd (1817825D HK)</a> applied to the Hong Kong Stock Exchange for a main board listing. JBM is a healthcare company headquartered in Hong Kong and a subsidiary of <a href="https://www.smartkarma.com/entities/jacobson-pharma" target="_blank" data-smartkarma-citation="entities:23579:1" rel="noopener">Jacobson Pharma (2633 HK)</a>. It is worth mentioning that another similar company, Tycoon Group (3390 HK) went public in 2020/1H. An indirect wholly-owned subsidiary of Jacobson participated in the HK$80m share subscription as a cornerstone investor. However, both Jacobson, which went public in 2016, and Tycoon Group, which went public in 2020, showed a volatile downward trend in the share price and didn’t perform well. This may be related to the limited growth potential in the industry, the lack of attractiveness, and the mediocre companies’ fundamentals. So could JBM break the ice?

In 2020Q3, JBM Healthcare Ltd (1817825D HK) applied to the Hong Kong Stock Exchange for a main board listing. JBM is a healthcare company headquartered in Hong Kong and a subsidiary of Jacobson Pharma (2633 HK). It is worth mentioning that another similar company, Tycoon Group (3390 HK) went public in 2020/1H. An indirect wholly-owned subsidiary of Jacobson participated in the HK$80m share subscription as a cornerstone investor. However, both Jacobson, which went public in 2016, and Tycoon Group, which went public in 2020, showed a volatile downward trend in the share price and didn’t perform well. This may be related to the limited growth potential in the industry, the lack of attractiveness, and the mediocre companies’ fundamentals. So could JBM break the ice?

Pre-IPO JBM Healthcare Ltd. - Could JBM Break the Ice?

Hong Kong

JBM (Healthcare) Limited provides health care testing services. The Company serves customers in the Cayman Islands.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JBM Healthcare Ltd (1817825D HK)

Primer: JBM Healthcare Ltd (1817825D HK) - May 2026

JBM Healthcare is a Hong Kong-based company engaged in the development, manufacture, and distribution of branded healthcare products, with a...

αSK Primers

Pre-IPO Xiamen Yan Palace Bioengineering (PHIP Updates) - Some Points Worth the Attention

As Yan palace's revenue growth further declines, effectiveness of marketing activities has already decrease. Huge selling expenses erode profit...

Xinyao (Criss) Wang

Pre-IPO JBM Healthcare Ltd. - Could JBM Break the Ice?

This article analyzed JBM Healthcare from the prospective of market potential, supplier concentration, and financial position, and summarized the...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)